INC280
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Hepatocellular Carcinoma With c-MET Dysregulation
Conditions
Advanced Hepatocellular Carcinoma With c-MET Dysregulation
Trial Timeline
Mar 25, 2013 → May 24, 2023
NCT ID
NCT01737827About INC280
INC280 is a phase 2 stage product being developed by Novartis for Advanced Hepatocellular Carcinoma With c-MET Dysregulation. The current trial status is terminated. This product is registered under clinical trial identifier NCT01737827. Target conditions include Advanced Hepatocellular Carcinoma With c-MET Dysregulation.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Hepatocellular Carcinoma With c-MET Dysregulation were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03240393 | Phase 2 | Withdrawn |
| NCT02925104 | Phase 1 | Completed |
| NCT02474537 | Phase 1 | Completed |
| NCT01737827 | Phase 2 | Terminated |
| NCT01324479 | Phase 1 | Completed |
| NCT01546428 | Phase 1 | Completed |
Competing Products
20 competing products in Advanced Hepatocellular Carcinoma With c-MET Dysregulation